Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Rafael Holdings, Inc. (RFL : NYSE)

• Company Description    Rafael Holdings Inc. manufactures metabolic oncology drugs to treat cancer. The company's product pipeline consists of CPI-613, CPI-618, CPI-1826 and CPI-3220 which are in clinical stages. Rafael Holdings Inc. is based in Newark, United States. Number of Employees: 31

• Price / Volume Information    Yesterday's Closing Price: $2.15 Daily Weekly Monthly 20 Day Moving Average: 279,543 shares Shares Outstanding: 35.09 (millions) Market Capitalization: $75.44 (millions) Beta: 0.97 52 Week High: $3.19 52 Week Low: $1.27 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -2.27% -5.93% 12 Week 27.98% 7.64% Year To Date 30.30% 22.03%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 520 BROAD STREET - NEWARK,NJ 07102 USA ph: 212-658-1450 fax: - invest@rafaelholdings.com http://www.rafaelholdings.com

• General Corporate Information    Officers William Conkling - Chief Executive Officer and President Howard S. Jonas - Chairman of the Board David Polinsky - Chief Financial Officer Susan Y. Bernstein - Director Stephen Greenberg - Director Peer Information Rafael Holdings, Inc. (GSAC) Rafael Holdings, Inc. (CASI) Rafael Holdings, Inc. (ALCD.) Rafael Holdings, Inc. (OMNN) Rafael Holdings, Inc. (CGPI.) Rafael Holdings, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 75062E106 SIC: 2834 Fiscal Year Fiscal Year End: July Last Reported Quarter: 04/01/25 Next Expected EPS Date: 11/05/25 Share - Related Items Shares Outstanding: 35.09 Most Recent Split Date: (:1) Beta: 0.97 Market Capitalization: $75.44 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.81 Price/Cash Flow: - Price / Sales: 103.06 EPS Growth vs. Year Ago Period: 86.03% vs. Previous Quarter: -216.67% Sales Growth vs. Year Ago Period: 7.74% vs. Previous Quarter: 370.13% ROE 04/30/25 - -24.75 01/31/25 - -58.04 10/31/24 - -53.71 ROA 04/30/25 - -21.12 01/31/25 - -51.35 10/31/24 - -48.78 Current Ratio 04/30/25 - 3.85 01/31/25 - 9.26 10/31/24 - 9.74 Quick Ratio 04/30/25 - 3.82 01/31/25 - 9.26 10/31/24 - 9.74 Operating Margin 04/30/25 - -2,710.93 01/31/25 - -6,716.15 10/31/24 - -6,867.00 Net Margin 04/30/25 - -3,127.60 01/31/25 - -7,148.16 10/31/24 - -5,707.03 Pre-Tax Margin 04/30/25 - -3,539.48 01/31/25 - -11,946.03 10/31/24 - -10,462.27 Book Value 04/30/25 - 2.64 01/31/25 - 2.90 10/31/24 - 3.14 Inventory Turnover 04/30/25 - 2.56 01/31/25 - - 10/31/24 - - Debt-to-Equity 04/30/25 - 0.00 01/31/25 - 0.00 10/31/24 - 0.00 Debt-to-Capital 04/30/25 - 0.09 01/31/25 - 0.10 10/31/24 - 0.10

Powered by Zacks Investment Research ©